When should apoB be measured? In whom should lipoprotein(a) be measured? Should LDL-C be calculated by the Friedewald, Martin-Hopkins, or Sampson-NIH equations? How do the PREVENT-ASCVD equations differ from the Pooled Cohort Equations? How long is a coronary artery calcium (CAC) score of 0 "good for"? How should CAC scoring be used to guide statin initiation and intensity? What are the new LDL-C, non-HDL-C, and apoB targets for secondary prevention? What counts as "very high-risk" ASCVD, and how does treatment differ? In which patients should bempedoic acid, inclisiran, or olezarsen be added? Watch for answers to these key questions and more in this "deep dive" of the 2026 ACC/AHA Guideline on the Management of Dyslipidemia.Watch on YouTube: https://youtu.be/yHXL_dH8zCo
Difficulty Level: Easy
You are listening to Hu Said: Guideline Lifeline
Please subscribe, rate, and support the channel! Ads help keep materials free for everyone.
Podden och tillhörande omslagsbild på den här sidan tillhör
Ruey Hu, MD, MPH. Innehållet i podden är skapat av Ruey Hu, MD, MPH och inte av,
eller tillsammans med, Poddtoppen.
